

October 29, 2026

BSE Limited
P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Scrip Code: 543904**Symbol: MANKIND**

Dear Sir/ Madam,

Subject: Intimation regarding re-affirmation/withdrawal of Credit Rating-CRISIL**Ref.: Regulation 30 & 51 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”)**

Pursuant to Regulations 30 and 51 read with Schedule III of the Listing Regulations, we wish to inform you that CRISIL Ratings Limited (“CRISIL”) vide its release dated October 29, 2026 has reaffirmed/withdrawn the credit rating for the following instruments of the Company:

Instruments	Amount (₹ in crore)	Rating	Rating Action
Non-Convertible Debentures	400	Crisil AA+/Stable	Reaffirmed
Non-Convertible Debentures	2,100	Crisil AA+/Stable	Reaffirmed
Non-Convertible Debentures	2,500	Crisil AA+/Stable	Withdrawn
Commercial Paper	1,500	Crisil A1+	Withdrawn

The detailed rationale provided by the CRISIL can be accessed by clicking on the link: [Rating Rationale](#)

The above information is also available on the website of the Company at www.mankindpharma.com.

This is for your information and records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

HITESH
KUMAR JAIN
Hitesh Kumar Jain
Company Secretary &
Compliance Officer

Digitally signed by
HITESH KUMAR JAIN
Date: 2026.10.29
20:23:19 +05'30'

MANKIND PHARMA LIMITED

Regd. Office : 208, Okhla Ind. Estate, Phase - 3, New Delhi-110020 • Ph. : 011-46846700, 47476600
CIN No. L74899DL1991 PLC044843 • E-mail : contact@mankindpharma.com • www.mankindpharma.com